Novel peptide-based HIV-1 immunotherapy

Expert Opinion on Biological Therapy

Volumn 4, Issue 3, 2004, Pages 349-361

  Sommerfelt, Maja A ^a   Nyhus, Jørgen ^a   Sørensen, Birger ^a  

^a Bionor Immuno AS   (Norway)

Author keywords

HIV 1 immunotherapy; Peptide; Therapeutic vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIRETROVIRUS AGENT; C4 V3; CD4 ANTIGEN; CD8 ANTIGEN; CLTB 36; ENV 2 3; EPITOPE; GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HGP 30; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; LIPO 4T; LIPO 5; LIPO 6; LIPO 6T; LIPOPEPTIDE; NEF PROTEIN; PEPTIDE; SYNVAC; TAB 9; TUBERCULIN; UNCLASSIFIED DRUG; VACC 4X; VACC 5Q; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BIOINFORMATICS; CLINICAL TRIAL; DENDRITIC CELL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOTHERAPY; NONHUMAN; PROTEIN DOMAIN; REVIEW; T LYMPHOCYTE; VIRUS STRAIN;

ANIMALS; CLINICAL TRIALS; DRUG DESIGN; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; PEPTIDES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 1642446678     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.3.349     Document Type: Review

References (98)

1. REDFIELD RR, BIRX DL, KETTER N et al.: A Phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N. Engl. J. Med. (1991) 324:1677-1684.
2. LINDENBURG CEA, STOLTE I, LANGENDAM MW et al.: Long-term follow up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine (2002) 20:2343-2347.
3. ROSENBURG ES, ALTFIELD M, POON SH et al.: Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 407:523-526.
4. ROBBINS GK, ADDO MM, TROUNG H et al.: Augmentation of HIV-1-specific Th cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS (2003) 17(8):1121-1126.
5. VITTINGHOFF E, SCHEER S, O'MALLEY P et al.: Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J. Infect. Dis. (1999) 179:717-720.
6. CARR A, COOPER DA: Adverse effects of antiretroviral therapy. Lancet (2000) 356:1423-1430.
7. FANTONI M, DEL BORGO C, AUTORE C: Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS (2003) 17(Suppl. 1):S162-S169.
8. WILSON JW: Update on antiretroviral drug resistance testing: combining laboratory technology with patient care. AIDS Read. (2003) 13(1):25-30, 35-8.
9. APPAY V, NIXON DF, DONAHOE SM et al.: HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. (2000) 192(1):63-75.
10. WILSON JDK, IMAMI N, WATKINS A et al.: Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus specificity equates with progression to disease. J. Infect. Dis. (2000) 182:792-798.
11. CHAMPAGNE P, OGG GS, KING AS et al.: Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 410(6824):106-111.
12. ALTFELD M, ALLEN TM, YU XG et al.: HIV-1 superinfection despite broad CD8+ T cell responses containing replication of the primary virus. Nature (2002) 420:434-439.
13. KLEIN MR, VAN BAALEN CA, HOLWERDA AM et al.: Kinetics of Gag-specific cytotoxic T lymphocyte responses during clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. (1995) 181:1365-1372.
14. RIVIERE Y, MCCHESNEY MB, PORROT F et al.: Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res. Hum. Retroviruses (1995) 11:903-907.
15. OGG GS, JIN X, BONHOEFFER S et al.: Quantitation of HIV-specific CTL and plasma load of viral RNA. Science (1998) 279:2013-2106.
16. OGG GS, KOSTENSE S, KLEIN MR et al.: Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with diseases progression. J. Virol. (1999) 73:9153-9160.
17. PONTESILLI O, KLEIN MR, KERKHOF-GARDE SR et al.: Longitudinal analysis of human immunodeficiency virus type-1 specific cytotoxic T lymphocyte response: a predominant gag-specific response is associated with nonprogressive infection. J. Infect. Dis. (1998) 178:1008-1018.
18. KAUL R, DONG T, PLUMMER FA et al.: CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J. Clin. Invest. (2001) 107:1303-1310.
19. KAUL R, PLUMMER FA, KIMANI J et al.: HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1 resistant prostitutes in Nairobi. J. Immunol. (2000) 164:1602-1611.
20. SHEDLOCK DJ, SHEN H: Requirement for CD4 T cell help in generating functional CD8 T-cell memory. Science (2003) 300:337-339.
21. SUN JC, BEVAN MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (2003) 300:339-342.
22. LAMBERT JS, REDFIELD RR, TRAMONT EC: Therapeutic human immunodeficiency virus vaccines: concept, current status and future directions. In: Antiretroviral Therapy. De Clercq EDA (Ed.), ASM Press, Washington DC (2001):219-242.
23. MOSS RB, GIERMAKOWSKA WK, SAVARY JR et al.: A primer on HIV type-1 specific immune function and Remune™. AIDS Res. Hum. Retroviruses (1998) 14(Suppl. 2):S167-S175.
24. CARCELAIN G, DEBRÉ, AUTRAN B: Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr. Opin. Immunol. (2001) 13:483-488.
25. LANGE CG, LEDERMAN MM: Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. J. Antimicrob. Chemother. (2003) 51(1):1-4.
26. WU Y, MARSH JW: Selective transcription and modulation of resting T-cell activity by preintegrated HIV. Science (2001) 293:1503-1506.
27. HERMANKOVA M, SILICIANO JD, ZHOU Y et al.: Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J. Virol. (2003) 77(13):7383-7392.
28. DEEKS SG, WRIN T, LIEGLER T et al.: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viraemia. N. Engl. J. Med. (2001) 344:472-480.
29. MILLER V: Structured treatment interruptions in antiretroviral management of HIV-1. Curr. Opin. Infect. Dis. (2001) 14:29-37.
30. MARTINEZ-PICADO J, MORALES-LOPETEGI K, WRIN T et al.: Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS (2002) 16:895-899.
31. LISZIEWICZ J, LORI F: Structured treatment interruptions in HIV/AIDS therapy. Microb. Infect. (2002) 4:207-214.
32. LORI F, FOLI A, LISZIEWICS J: Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects. J. Antimicrob. Chem. (2002) 50:155-160.
33. ARMBRUSTER C, STIEGLER GM, VCELAR BA et al.: A Phase I trial with two human monoclonal antibodies (hMab 2F5, 2G12) against HIV-1. AIDS (2002) 16(2):227-233.
34. FERRANTELLI F, RUPRECHT RM: Neutralising monoclonal antibodies against HIV - back in the major leagues? Curr. Opin. Immunol. (2002) 14:495-502.
35. RUPRECT RM, FERRANTELLI F, KITABWALLA M, XU W, MCCLURE HM: Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine (2003) 21:3370-3373.
36. RHODES T, WARGO H, HU W-S: High rates of human immunodeficiency virus type 1 recombination: near-random segregation markers one kilobase apart in one round of viral replication. J. Virol. (2003) 77(20):11193-11200.
37. MALIM M, EMERMAN M: HIV-1 sequence variation: drift, shift, and attenuation. Cell (2001) 104(4):469-472.
38. WEI X, DECKER JM, WANG S et al.: Antibody neutralisation and escape by HIV-1. Nature (2003) 422(6929):307-312. Discusses the concept of a glycan shield and how this promotes immune escape.
39. BAROUCH DH, KUNSTMAN J, KURODA MJ et al.: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 415:335-339.
40. PIERSON T, MCARTHUR J, SILICIANO RF: Reservoirs for HIV: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Ann. Rev. Immunol. (2000) 18:663-708. An in-depth overview of HIV reservoirs.
41. SAKSENA NK, POTTER SJ: Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev. (2003) 5(1):3-18.
42. KLEIN J, SATO A. The HLA System I. N. Engl. J. Med. (2001) 343:702-709. An in-depth overview of the HLA system, genes, structure and function.
43. KLEIN J, SATO A: The HLA System II. N. Engl. J. Med. (2001) 343:782-786.
44. TOMIYAMA H, AKARI H, ADACHI A, TAKIGUCHI M: Different effects of Nef-mediated class I downregulation on human immunodeficiency virus type 1-specific CD8+ T-cell cytolytic activity and cytokine production. J. Virol. (2002) 76:7535-7543.
45. KASPER MR, COLLINS KL: Nef-mediated disruption of HLA-A2 transport to the cell surface in T-cells. J. Virol. (2003) 77:3041-3049.
46. YANG OO, NGUYEN PT, KALAMS SA et al.: Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J. Virol. (2002) 76:1626-1631.
47. COHEN GB, GANDHI RT, DAVIS DM et al.: The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity (1999) 10(6):661-671.
48. STUMPTNER-CUVELETTE P, MORCHOISNE S, DUGAST M et al.: HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc. Natl. Acad. Sci. USA (2001) 98(21):12144-12149.
49. DOUEK DC, BRENCHLEY JM, BETTS MR et al.: HIV preferentially infects HIV-specific CD4+ T-cells. Nature (2002) 417:95-98.
50. FLAMAND L, CROWLEY RW, LUSSO P, COLOMBINI-HATCH S, MARGOLIS DM, GALLO RC: Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: Implications for HIV pathogenesis. Proc. Natl. Acad. Sci. USA (1998) 95:3111-3116.
51. ROSS RW, WRIGHT ME, TAVEL JA: Ongoing trials of immune-based therapies for HIV-1 infection in adults. Expert Opin. Biol. Ther. (2001) 1(3):413-424.
52. BERZOFSKY JA: Approaches and issues in the development of vaccines against HIV. J. Acquir. Immune Defic. Syndr. (1991) 4:451-459.
53. BERZOFSKY JA, BERKOWER IJ: Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-1995. AIDS (1995) 9(Suppl. A):S143-S157.
54. CHOPPIN J, COHEN W, BIANCO A et al.: Characteristics of HIV-1 Nef regions containing multiple CD8+ T cell epitopes: wealth of HLA-binding motifs and sensitivity to proteasome degradation. J. Immunol. (2001) 166(10):6164-6169.
55. KESSLER JH, BEEKMAN NJ, BRES-VLOEMANS SA et al.: Efficient identification of novel HLA-A 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. (2001) 193(1):73-88. One of the first papers discussing antigen processing within proteasomes.
56. DE GROOT AS, JESDAL B, MARTIN W et al.: Mapping cross clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine (2003) 21:4486-4504.
57. BERZOFSKY JA, AHLERS JD, BELYAKOV M: Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. (2001) 1(3):209-219. An extensive review on modern vaccine strategies.
58. TSOMIDES TJ, WALKER BD, EISEN HN: An optimal viral peptide recognised by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc. Natl. Acad. Sci. USA (1991) 88:11276-11280.
59. HUMPHREYS RE, ADAMS S, KOLDZIC G, NEDELESCU E, VON HOFE E, XU M: Increasing the potency of MHC class II-presented epitopes by linkage to Li-Key peptide. Vaccine (2000) 18:2693-2697.
60. KALLINTERIS NL, LU X, WU S et al.: Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine (2003) 21:4128-4132.
61. MOORE CB, JOHN M, JAMES IR, CHRISTIANSEN FT, WITT CS, MALALL SA: Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science (2002) 296:1439-1443.
62. KIM DT, MITCHELL DJ, BROCKSTEDT DG et al.: Introduction of soluble proteins into MHC class I pathway by conjugation to an HIV Tat peptide. J. Immunol. (1997) 159:1666-1668.
63. NYHUS J, SOMMERFELT MA, SØRENSEN B: Peptide from Tat basic domain shows striking similarity to a region of the human T-cell transcription factor (TCF)-1. AIDS Res. Hum. Retroviruses (2003) 19:345-346.
64. LIVINGSTON B, CRIMI C, NEWMAN M et al.: A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J. Immunol. (2002) 168:5499-5506.
65. ANDRIEU M, DESOUTTER J-F, LOING E et al.: Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J. Virol (2003) 77:1564-1570.
66. HICKLING JK: Measuring human T-lymphocyte function. Expert Rev. Mol. Med. (1998) 1:1-20.
67. NIETFELD W, BAUER M, FEVRIER M et al.: Sequence constraints and recognition by CTL of an HLA-B27 restricted HIV Gag epitope. J. Immunol. (1995) 154:2188-2197.
68. MANNERING SI, PURCELL AW, HONEYMAN MC, MCCLUSKY J, HARRISON L: Human T-cells recognise N-terminally Fmoc-modified peptide. Vaccine (2003) 21:3638-3646.
69. PINTO LA, BERZOFSKY JA, FOWKE KR et al.: HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS (1999) 13(15):2003-2012.
70. GORSE GJ, KEEFER MC, BELSHE RB et al.: A dose-ranging study of a prototype synthetic HIV-1MN V3 branched chain peptide vaccine. J. Infect. Dis. (1996) 173:330-339.
71. LAMBERT JS, KEEFER M, MULLIGAN M et al.: Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine (2001) 19:3033-3042.
72. PIALOUX GH, GAHÉRY-SÉGARD S, SERMET S et al.: Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS (2001) 15:1239-1249.
73. GAHÉRY-SÉGARD HG, PIALOUX B, CHARMETEAU S et al.: Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency type 1 lipopeptide vaccine. J. Virol. (2000) 74:1694-1703.
74. GAHÉRY-SÉGARD HG, PIALOUX G, FIGEUIREDO S et al.: Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterisation of CD8+-T-cells epitopes recognised. J. Virol. (2003) 77(20):11220-11231.
75. VELJKOVIC V, MÜLLER S, KÖHLER H: AIDSVAX results: an important open question. Vaccine (2003) 21:3528-3529.
76. BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245-252. A discussion of the potential of dendritic cells as a target for immunisation.
77. HEATH WR, CARBONE FR: Cross presentation in viral immunity and self tolerance. Nat. Rev. Immunol. (2001) 1:126-135. A generalised overview of cross-presentation.
78. ASJO B, STAVANG H, SORENSEN B, BAKSAAS I, NYHUS J, LANGELAND N: Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res. Hum. Retroviruses (2002) 18(18):1357-1365.
79. CARBONNEIL C, AOUBA A, BUGARD M et al.: Dendritic cells generated in the presence of granulocyte-macrophage colony stimulating factor and IFN-α are potent inducers of HIV-specific CD8 T cells. AIDS (2003) 17:1731-1740.
80. DHODAPKAR MV, STEINMAN RM: Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans. Blood (2002) 100:174-177.
81. SCHULER G, SCHULER-THURNER B, STEINMAN RM: The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. (2003) 15:138-147. A comprehensive review outlining the potential for dendritic cells within cancer immunotherapy.
82. LIU K, IYODA T, SATERNUS M, KIMURA Y, INABA K, STEINMAN RM: Immune tolerance after delivery of dying cells to dendritic cells in situ. J. Exp. Med. (2002) 196(8):1091-1097.
83. RUBINSTEIN A, MIZRACHI Y, PETTOELLO-MANTOVANI M et al.: Immunologic responses of HIV-1-infected study subjects to immunisation with a mixture of purified protein derivative-V3 loop peptide conjugates. J. AIDS (1999) 22:467-476.
84. RUBINSTEIN A, GOLDSTEIN H, PETTEOLLO-MANTOVANI M et al.: Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS (1995) 9(3):243-251.
85. AMOSCATO AA, PRENOVITZ DA, LOTZE MT: Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. (1998) 161:4023-4032.
86. GEEIJTENBEEK TB, KWON DS, TORENSMA R et al.: DC-SIGN, a dendritic cell-specific HIV-1 binding protein that enhances trans-infection of T-cells. Cell (2000) 100:587-597.
87. STEINMAN RM, GRANELLI-PIPERNO A, POPE M et al.: The interaction of immunodeficiency viruses with dendritic cells. Curr. Top. Microbiol. Immunol. (2003) 276:1-30.
88. STEINMAN RM, POPE M: Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. (2002) 109(12):1519-1526.
89. CHEN D, ZULEGER C, CHU Q, MAA YF, OSORIO J, PAYNE LG: Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses. AIDS Res. Hum. Retroviruses (2002) 18(10):715-22.
90. KEEFER MC, GRAHAM BS, MCELRATH MJ et al.: Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses (1996) 12(8):683-693.
91. KELLEHER AD, EMERY S, CUNNINGHAM P et al.: Safety and immunogenicity of UBI HIV-1 MN octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res. Hum. Retroviruses (1997) 13:29-32.
92. WANG CY, LOONEY DJ, LI ML et al.: Long-term high titre neutralizing activity induced by octameric synthetic HIV-1 antigen. Science (1991) 254(5029):285-288.
93. KAHN JO, STITES DP, SCILLIAN J et al.: A Phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue subunit vaccine in seronegative subjects. AIDS Res. Hum. Retroviruses (1992) 8:1321-1325.
94. BARTLETT JA, WASSERMAN SS, HICKS CB et al.: Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. AIDS (1998) 12:1291-1300.
95. EVANS TG, KEEFER MC, WEINHOLD KJ et al.: A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis. (1999) 180(2):290-298.
96. SALMON-CERON D, EXCLER JL, FINKIELSZTEJN L et al.: Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 MN tm/gag/protease LAI(ALVAC-HIV, vCP205) followed by p24-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res. Hum. Retroviruses (1999) 15(7):633-645.
97. CANO CA: The multi-epitope polypeptide approach in HIV-1 vaccine development. Genetic Analysis: Biomolecular Engineering (1999) 15:149-153.
98. SERWOLD T, GONZALEZ F, KIM J, JACOB R, SHASTRI N: ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature (2002) 419:480-483.